For example, in a diffuse glioma without morphological evidence of oligodendroglioma, IDH1 and ATRX analysis may be carried out initially, but would 1p/19q analysis still need to be performed in gliomas with ATRX mutation or loss of protein expression (ie, molecular evidence of astrocytoma)? This evidence concerns the gene ATRX and glioma.